Resistance to anticancer therapeutics greatly impacts the phenotypic and functional properties of 
Introduction
Resistance to anticancer modalities poses serious obstacles that must be addressed in order to improve the clinical prognosis for cancer patients. Recent studies have revealed that multiple mechanisms enable the development of resistance to anticancer therapies through genetic alterations and environmental modifications such as vascular and immunological remodeling within tumor tissues (1) (2) (3) (4) . Coordinated intrinsic and extrinsic pressures force tumor cells to accommodate to stressful microenvironments and co-opt multiple strategies for survival, invasion and distant metastasis, further enhancing tumorigenicity and worsening clinical prognosis. Accumulating evidence has established that rare populations termed cancer stem cells (CSCs) are indispensable as a main source of tumorigenicity and anticancer drug resistance (5) .
While it remains largely unclear whether chemoresistance further modifies the phenotypic and functional manifestations of CSCs, previous studies have revealed that the low sensitivity to cytotoxic therapies of CSCs derives mainly from cellular quiescence and multidrug transporter activity (6) .
In this study, we elucidate an unexpected property of CSCs derived from chemoresistant tumors 
Materials and Methods

Mice and tumor cell lines
NOD-SCID animals were purchased from Charles River. All experiments were conducted under a protocol approved by the animal care committees of Hokkaido University.
Tumor cell lines (MDA-MB-231 and HCT116) were obtained from the American Tissue Culture Collection (ATCC). All cell lines described above were obtained one year before being used in experiments and authenticated by the Central Institute for Experimental Animals (Kawasaki, Japan) for interspecies and mycoplasma contamination by PCR within 3 months before the experiments.
Patient samples
The clinical protocols for this study were approved by the committees in the Institutional Review Board of Hokkaido University Hospital (Approval number: 10-0114). Pleural effusion cells were obtained from patients with stage IV non-small cell lung carcinomas after written informed consents had been obtained. The cells were isolated by Ficoll-Hypaque density centrifugation, and further purified as EpCAM + epithelial cells and CD14 + monocytes from tumor tissues or pleural effusion.
Generation of chemoresistant tumor cells
To 
Flow cytometry
The expression levels of CD44 and ALDH1 for CSC-R and CSC-N were evaluated with antihuman CD44 Ab (BD Bioscience) and ALDEFOUR reagents (VERITAS), respectively. For myeloid cell analysis, monocytes stimulated with M-CSF, with supernatants of CSC-R or with those of CSC-N were stained with anti-CD206 Ab and anti-CD68 Ab (BD Bioscience). The cell viability of tumor cells treated cytotoxic drugs was examined by staining with annexin-V/propidium iodide staining according to the manufacturer's instructions (BD Bioscience). The cells were subjected to flow cytometry using a FACS Caliber.
Sphere forming assay
For sphere forming assays, CSC-R, CSC-N or bulk MDA-MB-231 cells primed with myeloid cells (1,000 cells per well) were cultured in ultra-low attachment culture dishes (Corning) in serum-free medium. DMEM/F-12 serum-free medium was supplemented with 20ng/mL epithelial growth factor and 10ng/mL basic-fibroblast growth factor-2 (PeproTech). Digestion and cell passage were performed every 3 days, and the sphere forming colonies were counted after three serial passages.
Measurement of cytokine and chemokines
CSCs, non-CSC or bulk cells from treatment-naïve or chemoresistant tumors (MDA-MB-231 or HCT116) (1 x 106/well at start point) were cultured for 48 h, and the protein levels of cytokines and chemokines were quantified by ELISA using supernatants obtained from cultured CSC-R and CSC-N according to the manufacturer's instructions (BD Biosciences). Detection limit for cytokines：IL-1β, 4 pg/mL; IL-6, 2 pg/mL; IL-8, 2pg/mL; IL-10, 7.8 pg/mL; IL-12p40, 15 pg/mL; TNF-α, 15 pg/mL; TGF-β, 19 pg/mL; GM-CSF, 9.4 pg/mL; M-CSF, 16.2 pg/mL; IFN-α, 15 pg/mL; IFN-γ, 10 pg/mL; CCL2, 2,3 pg/mL; CCL19, 7.8 pg/mL; CCL20, 7.8 pg/mL.
Quantification of cytokine mRNA by RT-PCR
The mRNA was isolated from CSC-R, CSC-N or these cells after transfection with control or IRF5 siRNA. The mRNAs of genes associated with myeloid cell differentiation (CSF1R, C/EBPα, and PU.1) or polarization (ARG-1, Relm-α, IL-4R) or effector functions (IL-10, IL12p70, CXCL9, IFN-γ) were quantified by real-time PCR using SYBR Green Gene Expression Assays (Applied Biosystems).
Luciferase reporter assay for NF-κB and ISRE
CSC-R or CSC-N from MDA-MB-231 or HCT116 were treated with taxane or CDDP, as a ratio of firefly reporter intensities to control renilla intensities.
Immunoblotting
CSC-R or CSC-N from MDA-MB231 or HCT116 was subjected to Western blotting to quantify the protein levels of IRF-5 by using antibodies for human IRF5 Ab (Cell Signaling Technologies). Beta-actin was used as a loading control to check the integrity of each sample.
RNA interference
The siRNA-mediated knockdown was performed by On-target plus SMART pool reagents designed to target human IRF5 (Thermo-Dharmacon). The human IRF5 or control siRNAs were does not render non-CSC with plasticity to undergo trans-differentiate into CSCs.
In vivo tumorigenic activities of primary NSCLC tumors
Together, our findings potentially suggest that CSC-N undergoes intrinsic genetic and/or epigenetic alternation to transform into the CSC-R upon chronic exposure with cytotoxic drugs, but further studies should be required for defining this possibility by comprehensive genetic analysis.
Proinflammatory profile of cancer stem cells derived from chemoresistant tumor cells
Inflammatory signals play a critical role in the regulation of the stem cell characteristics and tumorigenic activities of CSCs through autocrine and paracrine-mediated mechanisms (9-11).
We therefore next evaluated the possibility that chemoresistance modifies inflammatory profiles in CSCs from MDA-MB-231. To our surprise, we found that mRNA levels of various cytokines and chemokines, such as IL-1β, IL-6, IL-8, IL-12p40, TNF-α, M-CSF and CCL2 were produced in CSC-R subsets at higher amounts compared to the bulk tumor cell counterparts, although bulk chemoresistant cells could produce proinflammatory mediators at higher levels than CSC-N or treatment-naïve bulk tumor cells ( Figure 2A and Supplementary Figure   2A ). We also confirmed the higher protein levels of several cytokines (M-CSF, IL-1β, IL-6 and TNFα) in CSC-R compared to bulk or non-CSC populations ( Figure 2B and data not shown).
Consistent with its proinflammatory activities, the transcriptional activity of NF-κB was higher in CSC-R compared to CSC-N ( Figure 2C ). We observed similar trends in CSC-R from HCT- Figure 2A) . Furthermore, the chemotherapy-naïve CSCs from MDA-MB-231 cells did not produce pro-inflammatory cytokines such as M-CSF when they were treated with cytotoxic drug taxane for a brief period, suggesting that acute stress responses changes evoked by exposure of cytotoxic drugs had little effects in modifying inflammatory profiles of CSCs (Supplementary Figure 3A) . Taken together, our findings suggest that chemoresistance rendered CSCs with the ability to triggers autocrine activation of inflammatory signals, which subsequently resulted in the production of proinflammatory mediators.
(Supplementary
CSC-R prime monocytes to differentiate into M2 macrophages
Given the characteristic proinflammatory cytokine profiles of CSC-R, we focused our study on the effects of CSC-R-mediated inflammatory signals on phenotypic and functional properties of macrophages, since myeloid cells have a tremendous impact on the regulation of tumorigenic activities and anticancer drug resistance (12, 13) . Macrophages express several immunoregulatory genes that are closely linked with impaired tumor immunosurveillance (14) . Figure   3D ). More importantly, human CD68 + macrophages expressing the putative M2 marker CD163
and CD206 were infiltrated into the tumor tissues of CSC-R at greater levels than those of CSC-N ( Figure 3E ). In contrast, the frequencies of CD163 low HLA-DR high M1 macrophages were comparable in tumors from CSC-R and CSC-N ( Figure 3E ). Together, these results further support our hypothesis that CSC-R specifically regulates infiltration and differentiation of immunoregulatory M2-macrophages. Figure 3B) .
Together, these results suggested that soluble factors released from CSC-R may regulate the differentiation of immunosuppressive macrophages from monocyte precursors, which have a great impact on tumorigenicity.
Upregulation of IRF5 promotes M-CSF production from CSC-R
In addition to NF-κB-mediated inflammatory signals, transcriptional activities mediated by interferon-stimulated response elements (ISRE) were detected in CSC-R at much higher levels than those in CSC-N ( Figure 4A ). In contrast, type-I interferon and transcriptional activities of interferon-γ-activation sequences (GAS) were detected in CSC-R at levels similar to those in CSC-N upon chemotherapy ( Figure 4A ).
Given that IFNs signal through JAK/STAT pathways to induce interferon-stimulation genes Figure 4B ). We also confirmed that the mRNA levels of IRF5 expression were detected in CSC-R at much higher levels than parental tumors or CSC-N, and the protein levels of IRF5 were also higher in CSC-R from MDA-MB231 and HCT116 compared to the CSC-N counterparts ( Figure 4C and D) . 
Clinical significance of IRF5-M-CSF pathways
Finally, we sought to determine whether our observations could be verified in the clinically relevant settings. To do so, we obtained pleural effusion cells from patients with stage IV nonsmall cell lung cancer (NSCLC) to check the mRNA levels of IRF5 and M-CSF in EpCAM + epithelial cells. We also analyzed total numbers of CSF1 receptor (CSF1R)-positive macrophages in NSCLC tumors, which have been known as tumorigenic and immunosuppressive subsets in human cancers (20, 21) . We found that mRNA levels of IRF5 were highly correlated with those of M-CSF in tumor tissues in patients with NSCLC ( Figure 6 ). 
pathways were not correlated with total numbers of CD68 + macrophages ( Figure 6 ). Finally, the expression levels of CSC maker ALDH1 mRNA was also correlated with the those of IRF5, M-CSF, as well as CSF1R + cell numbers ( Figure 6 ). Together, these findings support the notion that IRF5/M-CSF pathway positively regulates tumorigenic myeloid cells and CSC activities in cancer patients. We demonstrated that IRF5-dependent induction of M-CSF is a key step in the generation of tumorigenic myeloid cells by CSC-R. Although the molecular mechanisms by which CSC-R regulate M-CSF production remain to be defined, several transcription factors, such as PU.1, C/EBP-α and NF-κB, may coordinate with IRF5 to regulate specific sets of cytokines and growth factors. Moreover, PU.1 associates with various types of IRFs to amplify its transcriptional activities, which greatly modifies the immunological functions of myeloid cells in multiple ways (26) (27) (28) (29) . Thus, it is tempting to speculate that IRF5 may cooperate with various myeloid cell differentiation factors in CSC-R and that such cooperation may be critically involved in the genetic and epigenetic control of M-CSF expression.
Discussion
We also found that CSC-R have unique propensities to activate inflammatory signals thus inducing multiple sets of cytokines and chemokines. Among them, TNF-α, IL-6 and IL-8 have emerged as tumorigenic mediators that link various inflammatory signals with oncogenic cascades to create tumorigenic microenvironments (30) (31) (32) . In addition, CCL2 supports the recruitment of CCR2 + inflammatory monocytes into tumor tissues, which serves as a key step in generating tumorigenic macrophages (33, 34) . Thus, it is important to address how the distinct and coordinated actions of these inflammatory mediators impact the tumorigenicity and anticancer drug responses of CSCs within the privileged tumor microenvironments.
In conclusion, we provide a novel pathway whereby responsiveness to anticancer drugs 
